1. Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res 2021; 51: 1013-1025.
2.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77: 1797-1835.
3.
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81: 492-542.
4.
Tamai H, Okamura J, Nanjo K. Moderate-carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study. Hepatol Res 2023; 53: 1185-1197.
5.
Blair HA. Pemafibrate: First global approval. Drugs 2017; 77: 1805-1810.
6.
Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 2017; 16: 124.
7.
Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021; 54: 1263-1277.
8.
Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 2015; 45: 363-377.
9.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
10.
Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
11.
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol 2017; 112: 18-35.
12.
Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38: 134-143.
13.
Shinozaki S, Tahara T, Lefor AK, et al. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2020; 6: 270-274.
14.
Shinozaki S, Tahara T, Lefor AK, et al. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol 2021; 7: 172-177.
15.
Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. Hepatol Res 2020; 50: 1328-1336.
16.
Ikeda S, Sugihara T, Hoshino Y, et al. Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease. Yonago Acta Med 2020; 63: 188-197.
17.
Hatanaka T, Kakizaki S, Saito N, et al. Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: A retrospective, single-arm study. Intern Med 2021; 60: 2167-2174.
18.
Hatanaka T, Kosone T, Saito N, et al. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 2021; 5: 1183-1189.
19.
Shinozaki S, Tahara T, Miura K, et al. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clin Exp Hepatology 2022; 8: 278-283.
20.
Shinozaki S, Tahara T, Miura K, et al. Effectiveness of one-year pemafibrate therapy on non-alcoholic fatty liver disease refractory to long-term sodium glucose cotransporter-2 inhibitor therapy: A pilot study. Life 2023; 13: 1327.
21.
Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med 2023; 10: 1073025.
22.
Ishikawa T, Terai N, Igarashi T, et al. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease. Clin Exp Hepatol 2023; 9: 172-178.
23.
Ono H, Atsukawa M, Tsubota A, et al. Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study. JGH Open 2024; 8: e13057.
24.
Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 2023; 17:
25.
606-614.
26.
Iwadare T, Kimura T, Kunimoto H, et al. Long-term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD. Front Endocrinol 2024; 15: 1329294.
27.
Kikuchi M, Kikuchi M, Konishi M. Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia. Clin Exp Hepatol 2024; 10: 182-187.
28.
Yamada-Shimizu M, Tamaki N, Kurosaki M, et al. A comparison of alanine aminotransferase normalization between pemafibrate and bezafibrate in patients with nonalcoholic fatty liver disease. Intern Med 2024; 63: 1185-1190.
29.
Iwadare T, Kimura T, Okumura T, et al. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease. Commun Med (Lond) 2024; 4: 73.
30.
Kamada Y, Sumida Y, Takahashi H, et al. Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review. J Gastroenterol 2025; 60: 10-23.
31.
Iwadare T, Kimura T, Kunimoto H, et al. Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD. Biomedicines 2022; 10: 2806.
32.
Shinozaki S, Miura K, Tahara T, et al. Effectiveness of pemafibrate dose escalation on metabolic dysfunction-associated steatotic liver disease refractory to standard dose. Metabolites 2025; 15: 100.
33.
Yamaguchi M, Asano T, Arisaka T, et al. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol Res 2022; 52: 522-531.
34.
Tamai H, Okamura J. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease. Hepatol Res 2023; 53: 258-266.
35.
Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol 2023; 38: 921-929.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
